Month: August 2021

Aktsiaselts Tallink Grupp (the Company) intends to conduct a public offering of the new shares of the Company in Estonia and Finland (in Finland in the form of the Finnish depositary receipts, FDRs). The intended subscription period of the new shares is contemplated to be 18.08.2021 (including) – 01.09.2021 (including). Conducting the public offering is subject to the approval of a public offering and listing prospectus by the Financial Supervision Authority, the proceedings of which are currently pending. The Company will issue a separate notice on the public offering of the new shares after the approval of the public offering and listing prospectus by the Financial Supervision Authority but before the beginning of the offering. The Company intends to offer up to 66,988,204 new shares. Upon oversubscription, the Company may increase the...

The retail turnover (including VAT) of Apranga Group amounted to EUR 22.4 million in July 2021 and increased by 15.1% compared to July 2020. In July 2021, the retail turnover of Apranga Group in Lithuania increased by 18.4% year-to-year, in Latvia increased by 14.7% and in Estonia increased by 4.6%. Due to epidemic coronavirus (COVID-19) infection, from 16 December 2020, all the Group’s stores in Lithuania were temporarily closed. Stores in Lithuania with a separate entrance from outside and a sales area not exceeding 300 square meters had been open since 15 February 2021. All stores with a separate entrance from outside had been open since 15 March 2021. All Group’s stores have been reopened in Lithuania from 19 April 2021, however, stores operating in shopping malls were not allowed to work on weekends, unless they had separate entrance...

Nasdaq OMX Copenhagen                                                     Skjern, 3. august 2021Nikolaj Plads 61007 København K Fondsbørsmeddelelse nr. 10/2021 Indberetningspligtiges transaktioner med Skjern Bank A/S-aktier Skjern Bank A/S indberetter hermed på vegne af bankens indberetningspligtige transaktioner med Skjern Bank-aktier i henhold til Markedsmisbrugsforordningens artikel 19. For yderligere detaljer henvises til vedhæftede skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til dem skal indberettes og offentliggøres. Med venlig hilsenSkjern Bank Per MunckBankdirektør Vedhæftet fil:IndberetningsskemaerAttachments10_2021 Indberetningspligtiges transaktionerSkema transaktioner i august 2021

Reference is made to the earlier information provided about the ongoing financial process with the lenders, the latest in a press release dated 16 July 2021 to Prosafe SE’s and Prosafe Rigs Pte. Ltd.’s (“PRPL”) applications for leave of the Singapore Court to convene meetings of its creditors to vote on proposed schemes of arrangement pursuant to section 210(1) of the Singapore Companies Act in HC/ OS 711/ 2021 and HC/ OS 712/2021 (the “Convening Applications”). At the Convening Applications hearing today, the Singapore Court granted the Convening Applications in full. Among other things, the Singapore Court made the following orders: 1. Leave be granted to Prosafe SE and PRPL to convene the Scheme Meetings pursuant to Section 210(1) of the Singapore Companies Act, for the purpose of considering and,...

Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the study Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the productPARIS and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) — Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”) is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the top line results of the SARA-INT phase 2...

Amsterdam, 2 August 2021 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) announces: KEY HIGHLIGHTSThe net result of Heineken Holding N.V.’s participating interest in Heineken N.V. for the first half year of 2021 amounts to €517 million Net revenue (beia) €9,971 million, +14.1% organic growth Net revenue (beia) organic growth per hectolitre +5.5% Consolidated beer volume organic growth +9.6% Heineken® volume +19.6% Operating profit (beia) organic growth +109.3% Net profit (beia) €896 million, +320.3% organic growth EverGreen strategy deployment at HEINEKEN has started Full year expectations unchanged: financial results to remain below 2019. FINANCIAL SUMMARY1IFRS Measures € million Total growth   BEIA Measures € million Organic growth2Revenue 11,970    7.3  %  ...

Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 ET / 07:00 PT) the same day. Title:                Addex Half-Year 2021 Financial ResultsDate:               August 5, 2021Time:               16:00 CEST (15:00 BST / 10:00 ET / 07:00 PT) Joining the Conference Call:1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in...

Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) – Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. “It’s great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex and our research programs,” said Tim Dyer, CEO of Addex. “We look forward to his contribution to our pipeline as we advance multiple...